Ivonescimab extended overall survival in a phase 3 study of first‑line treatment for PD‑L1‑positive non‑small cell lung cancer, the data showed at the 2024 World Conference on Lung Cancer.
Phase 3 HARMONi‑2 trial reports longer survival
The trial, conducted in China, compared the antibody plus chemotherapy with MSD’s PD‑L1 inhibitor Keytruda (pembrolizumab). Progression‑free survival rose from 5.82 months to 11.14 months, nearly a two‑fold increase. The study also indicated a statistically significant and clinically meaningful overall‑survival advantage, although the exact figure has not yet been disclosed.
Regulators view overall survival as a sturdier efficacy marker than progression‑free intervals, and the improvement strengthens the case for broader approval and reimbursement. The drug already holds a Chinese monotherapy indication for PD‑L1‑positive non‑squamous disease based on earlier progression‑free data.
In addition, it is approved as a second‑line option for EGFR‑mutated non‑squamous lung cancer and as a first‑line regimen for squamous disease when paired with chemotherapy, according to the HARMONi‑6 study.
Regulatory outlook and market expectations
U.S. regulators are slated to issue a decision in November for the EGFR‑mutated indication, a move that could open doors in other markets. A $5 billion licensing agreement gave Summit rights outside Greater China, with a $500 million upfront payment in 2022.
Earlier enthusiasm waned after the international HARMONi‑3 interim analysis missed its progression‑free endpoint, raising doubts about efficacy in Western cohorts. Yet later data from HARMONi‑6 and the biliary‑tract cancer study HARMONi‑GI1 revived interest.
Some analysts note that the drug’s performance appears to taper with longer follow‑up in certain studies, a sign that durability may be an issue. The upcoming readout from HARMONi‑3, expected before year‑end, should clarify whether the benefit seen in Chinese patients translates abroad.
The ongoing HARMONi‑7 trial pits the agent against Keytruda in an international PD‑L1‑positive lung‑cancer group, directly testing the hypothesis that the combination can outperform the current standard.
Related: PMV prepares to file first p53 cancer therapy
Looking ahead, the next few months will likely determine whether the therapy secures a foothold beyond its home market. If the pending U.S. filing is positive, insurers may begin to consider coverage, which could influence pricing negotiations worldwide.
Given the current data, the drug’s trajectory seems cautiously optimistic, but the ultimate market impact will hinge on broader trial outcomes and regulatory verdicts.
Ivonescimab belongs to a class of PD‑1 × VEGF inhibitors, a dual‑target approach that seeks to block both immune checkpoint signaling and tumor‑driven angiogenesis. The HARMONi‑2 outcome marks the first phase 3 trial to demonstrate a measurable overall‑survival gain over Keytruda in a first‑line setting, a milestone that shows the therapeutic potential of combining checkpoint inhibition with vascular targeting.
Beyond lung cancer, the molecule has already shown activity in biliary‑tract malignancies, where the HARMONi‑GI1 study reported significant overall‑survival improvements. Those results, together with the positive signals from HARMONi‑6, have helped restore confidence after earlier data suggested limited benefit in non‑Chinese populations.
The Chinese monotherapy approval for PD‑L1‑positive non‑squamous NSCLC was originally based on progression‑free survival outcomes, illustrating how early efficacy signals can translate into regulatory acceptance even before overall‑survival data are available. This regulatory pathway paved the way for subsequent label extensions to second‑line EGFR‑mutated disease and first‑line squamous disease, each anchored by separate trial programs.
Analysts continue to monitor the durability of response, noting that extended follow‑up in HARMONi‑6 hinted at a gradual attenuation of benefit. Such observations fuel ongoing discussions about optimal sequencing and combination strategies, especially as competitors introduce next‑generation checkpoint inhibitors.
Summit’s acquisition of rights outside Greater China, secured through a multibillion‑dollar agreement, reflects the strategic importance placed on ivonescimab’s potential to challenge an established $32 billion‑a‑year blockbuster. The sizable upfront payment shows confidence in the drug’s commercial prospects, provided that forthcoming international trial data confirm the efficacy trends observed in Chinese cohorts.
